Score audit
superduperinvst @superduperinvst
Every input is listed below — the score is the Wilson lower bound of the win rate over the decided calls, so anyone can recompute it. Methodology
Resolved calls (12)
9 wins + 2 losses = the decided base; 1 breakevens are resolved but carry no win/loss signal, so they sit outside it.
“$VBIO - LOAD UP on dips, I see it rising to $5 to $25 in NT/LT imo.”
“$NRXP $3.15 - LOAD UP and add on any further dips. Fearlessly buying as I believe this stock will be seen between $6.25 - $15 range by the end of this year imo”
“$VBIO <$2.50 rn - Will for sure see between $3 - $7 in ST and with PAYtience in NT it will likely be seen at $5 - $15 imo.”
“$FLY <$21 = SCREAMING BUY. My NT PT is $30 - $55 imo 🤑”
“$CBRS <$178 - BUY you will for sure 100% get chance to sell at between $200 - $250 before year end imo.”
“$CBRS <$178 = LOAD LOAD LOAD UP and keep adding on dips if you have vision and PAYtience. Someday day in the future stock will jump $25 - $50 upon big news. My LT PT is $350+ imo.”
“$NRXP <$3.50 = BUY, 90% chances of FDA approval before end of 2026 the news of which could lift this stock to $7 to $13 range quickly. Company aims for 2026 approval and commercialization on its Preservative-Free Ketamine. Accordingly, five million units of launch stock is currently in the manufacturing process with anticipated post launch manufacture of 1 million units per month per mgmt imo https://t.co/jDiImauoKZ”
“$AMLX - Going to start 1 st lot short position at $41.25+ with tight SL at $42.55 Stock is worth no more than $28 even with the recent positive phase 3 data because it is 2 yrs away even IF FDA approves the drug. Even post approval it will take few years to even generate $200 mln in sales. Current stock price that has jumped up from $7 to $40+ making mkt cap of $5.5+ bln makes this too rich and VERY OVERVALUED factoring everything imo.”
“$VBIO - Accumulating on dips. One good news and this thing can suddenly fly to $0.30 to $0.75 Not much to lose from 13 cents buys imo”
“$VBIO <$0.16 = SCREAMING BUY for risk takers and investors with PAYtience. Float is getting into tight hands. This should be a $1+ stock even right now given the incredible progress they have made so far in last 5+ yrs and the very late stage rich explosive demand pipeline. With or without RS (hopefully soon without we see surge back to $1 - $2+) someday this will be $5+ stock imo 🤑”
“$FGI $16.50+ rn - Be VERY CAREFUL chasing it in FOMO. Take your profits and run. It may spike some more but it would be great time to Sell or Short Sell on spike. It will be back to $5 - $10 as they have heavy debt and are cash strapped and will be doing dilution any day imo.”
“$SNOA <$1.30 = Current mkt cap <$6 mln. Stock should be at least at $5 or much higher given the strong fundamentals and considering everything. LOAD UP it is dirt cheap. Read this ER and you will see for yourself why this is the cheapest Pharma company stock imo https://t.co/3XM7DpaFaZ”
Falsifiable, not yet decided (4)
Open or untriggered — these count against coverage until they resolve.
“$VNDA <$4.95 rn = <$300 mln mkt cap = SCREAMING BUY !!!!! Time for me to LOAD LOAD LOAD, fearlessly add on dips and hold with PAYtience to sell someday in range of between $15 - $50 in NT/LT. Numerous upcoming Catalysts in ST/NT. Vanda Pharmaceuticals has multiple clinical readouts, commercial launches, and regulatory milestones scheduled through late 2026 and the first half of 2027 imo: BYSANTI (milsaperidone) Commercial Launch: Rolling out in the second half of 2026 following its Q1 2026 FDA approval for Schizophrenia and Bipolar I disorder, aiming for a favorable gross-to-net profile. NEREUS (tradipitant) Commercial Scaling: Continued market expansion following its May 2026 launch for motion sickness through direct-to-consumer and traditional channels. HETLIOZ (tasimelteon) Public Hearing: Ongoing proceedings regarding the rare FDA formal evidentiary public hearing for jet-lag disorder. Late-Stage Clinical Readouts: Multiple pipeline readouts expected before year-end 2026 and into H1 2027 spanning studies for HETLIOZ, NEREUS, VQW-765, and BYSANTI. Tradipitant GLP-1 Program: Preparation and progression toward a planned Phase III clinical program evaluating tradipitant for reducing Wegovy-induced nausea and vomiting.”
“$VNDA $5 - $5.25 range - Someday you will regret not loading up as many as you could have at around $5. This is going to be in $15 - $50 range within next 3 yrs imo.”
“$AVEX $18's - Will be seen someday between $35 - $100 within 3 yrs so investors with vision and PAYtience start loading up, hold tight and add on dips imo.”
“$BCDA <$0.95 - NOW is the BEST TIME to start building a long position for ST/NT & LT in this HEART FAILURE - CARDIOLOGY & PULMONARY sector play. Break $1 this will attract many hedge funds to start buying given this stock used to be $40+ and with what's coming in next 1 to 2 yrs, this has likelihood of jumping 500% to 1500% over the time with PAYtience imo.”
No falsifiable level (24)
Calls with no stated target or stop can't be scored — they feed the unverified 1-Week Read instead and count against coverage. Not listed individually.
Call text is shown as captured at seed time; deleting the post on X does not remove it here. This audit is a record of public calls and their market outcomes — not financial advice, and never a recommendation. Dispute an attribution: claim this profile to correct it.